Trial Profile
A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CD22 anti CD19 monoclonal antibody toxin conjugate (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 09 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Nov 2006 New trial record.